Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen

European Journal of Haematology

Volumn 90, Issue 2, 2013, Pages 157-161

  Kamimura, Tomohiko ^a   Miyamoto, Toshihiro ^b   Yokota, Noriko ^a   Takashima, Shuichiro ^b   Chong, Yong ^a,b   Ito, Yoshikiyo ^a   Akashi, Koichi ^b  

^a HARASANSHIN HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Bortezomib; Injection; Multiple myeloma; Site reaction; Subcutaneously

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE;

ABDOMEN; ADIPOSE TISSUE; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INJECTION SITE REACTION; JAPANESE; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 84872781052     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12055     Document Type: Article

References (16)

1. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:303-9.
2. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematology Am Soc Hematol Educ Program 2011;2011:191-6.
3. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
4. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95:311-9.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144:895-903.
6. Lonial S. Is subcutaneous bortezomib ready for prime time? Curr Hematol Malig Rep 2011;6:73-4.
7. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11.
8. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40.
9. Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012 Jun 11. doi: 10.3324/haematol.2012.067793. PubMed PMID: 22689676.
10. Mader I, Fürst-Weger P, Made R, Nogler-Semenitz E, Wassertheurer S. Extravasation of cytotoxic agents: compendium for prevention and treatment. Wien, NY: Springer, 2010. 127-9.
11. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012;51:823-9.
12. Fukushima T, Nakamura T, Iwao H, et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 2011;31:2297-302.
13. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416-7.
14. Obeid KM, Ferrara R, Sharma M. Cutaneous lesion induced by a subcutaneous administration of bortezomib. Clin Lymphoma Myeloma Leuk 2012;12:284-6.
15. Kamimura T, Miyamoto T, Takashima S, Yokota N, Chong Y, Ito Y, Akashi K. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma. Int J Hematol 2012;96:525-7.
16. Snijder MB, Visser M, Dekker JM, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The health ABC study. Diabetologia 2005;48:301-8.